CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Hata Yujiro S President and CEO | Sale 10b5-1 | −53,592 | $42.57 | $2.3M | 708,151 |
| 2024-05-15 | Hata Yujiro S President and CEO | Sale 10b5-1 | −29,761 | $43.48 | $1.3M | 678,390 |
| 2024-05-15 | Hata Yujiro S President and CEO | Sale 10b5-1 | −503 | $44.12 | $22K | 677,887 |
| 2024-05-15 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −83,856 | 83,887 | ||
| 2024-05-14 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +56,711 | $4.31 | $244K | 734,598 |
| 2024-05-14 | Hata Yujiro S President and CEO | Sale 10b5-1 | −54,408 | $41.60 | $2.3M | 680,190 |
| 2024-05-14 | Hata Yujiro S President and CEO | Sale 10b5-1 | −2,303 | $41.84 | $96K | 677,887 |
| 2024-05-14 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −56,711 | 167,743 | ||
| 2024-03-01 | Hata Yujiro S President and CEO | Grant or award · Stock Option (right to buy) | +480,000 | 480,000 | ||
| 2024-03-01 | Ruiz Briseno Andres See Remarks | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2024-03-01 | Beaupre Darrin Chief Medical Officer | Grant or award · Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2024-03-01 | WHITE MICHAEL ANTHONY Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2024-03-01 | Throne Jason Chief Legal Officer | Grant or award · Stock Option (right to buy) | +125,500 | 125,500 | ||
| 2024-02-09 | Ruiz Briseno Andres See Remarks | Sale 10b5-1 | −2,000 | $46.02 | $92K | 24,531 |
| 2024-02-09 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +23,557 | $4.31 | $102K | 701,444 |
| 2024-02-09 | Hata Yujiro S President and CEO | Sale 10b5-1 | −23,557 | $45.54 | $1.1M | 677,887 |
| 2024-02-09 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −23,557 | 224,454 | ||
| 2024-02-08 | Hata Yujiro S President and CEO | Option exercise 10b5-1 | +75,815 | $4.31 | $327K | 753,702 |
| 2024-02-08 | Hata Yujiro S President and CEO | Sale 10b5-1 | −75,815 | $45.15 | $3.4M | 677,887 |
| 2024-02-08 | Hata Yujiro S President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −75,815 | 248,011 |
Page 4 of 10 · 186 trades